Replimune (REPL) Liabilities and Shareholders Equity (2018 - 2025)

Replimune has disclosed Liabilities and Shareholders Equity across 8 years of filings, most recently posting $333.6 million for Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $333.6 million, down 44.74% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.7 billion (down 17.92% YoY), and the FY2025 annual result was $551.3 million, up 13.04% from the prior year.
• Liabilities and Shareholders Equity came in at $333.6 million for Q4 2025 at Replimune, down from $389.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $678.6 million in Q4 2022 to a low of $333.6 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $513.6 million (2021), against an average of $515.3 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 132.0% in 2021 and slumped 44.74% in 2025, its largest moves.
• Replimune's Liabilities and Shareholders Equity stood at $485.3 million in 2021, then surged by 39.83% to $678.6 million in 2022, then slipped by 21.46% to $532.9 million in 2023, then rose by 13.27% to $603.6 million in 2024, then slumped by 44.74% to $333.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $333.6 million (Q4 2025), $389.4 million (Q3 2025), and $469.5 million (Q2 2025), per Business Quant data.